Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kellie Berry Hert

Nurse Practitioner, Psychiatric/Mental Health Fort Smith, AR Nurse Practitioner

NPI 1710026257 CMS profile 10448651

3111 S 70Th St, Fort Smith, AR 72903

Open in the dashboard

General payments

$4,435

217 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kellie Berry Hert of Fort Smith, AR is reported in the CMS Open Payments database as having received $4,435 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $444 23
2024 General $561 18
2023 General $1,743 85
2022 General $690 38
2021 General $997 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kellie Berry Hert
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Kellie Berry Hert were reported at $444. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Kellie Berry Hert Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $997 $166 $54–$482 $132
2022 $690 $195 $66–$559 $149
2023 $1,743 $233 $82–$673 $160
2024 $561 $236 $84–$688 $164
2025 $444 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,792 99 payments
  2. ITI, Inc. $652 34 payments
  3. Janssen Pharmaceuticals, Inc $437 18 payments
  4. Neurocrine Biosciences, Inc. $344 17 payments
  5. Otsuka America Pharmaceutical, Inc. $324 12 payments
  6. Axsome Therapeutics, Inc. $263 3 payments
  7. Alkermes, Inc. $232 10 payments
  8. Sunovion Pharmaceuticals Inc. $105 9 payments
  9. Vanda Pharmaceuticals Inc. $88 4 payments
  10. Teva Pharmaceuticals USA, Inc. $78 4 payments
  11. Other $121 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,414 215 payments
  2. Travel and Lodging $12 1 payment
  3. Education $8 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,474 82 payments
  2. CAPLYTA $621 32 payments
  3. REXULTI $324 12 payments
  4. VRAYLAR Neuroscience $317 17 payments
  5. INVEGA SUSTENNA $288 16 payments
  6. Auvelity $263 3 payments
  7. ARISTADA Cns $232 10 payments
  8. ARISTADA Cns $232 10 payments
  9. ARISTADA Cns $232 10 payments
  10. ARISTADA Cns $232 10 payments
  11. Other $1,498 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,385

Median for Nurse Practitioner: 389

Drug cost

$278,502

Median for Nurse Practitioner: $21,885

Branded share of claims

16.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 11 $89,276
Vraylar Cariprazine Hcl Brand 39 $57,922
Invega Sustenna Paliperidone Palmitate Brand 17 $55,250
Aristada Aripiprazole Lauroxil Brand 12 $37,981
Lurasidone Hcl Generic 42 $4,453
Chlorpromazine Hcl Generic 16 $2,794
Paliperidone Er Paliperidone Brand 15 $1,938
Aripiprazole Generic 51 $1,694
Quetiapine Fumarate Generic 143 $1,670
Buspirone Hcl Generic 91 $1,533

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $263
$263 — —
VRAYLAR
  • AbbVie, Inc. $212
$212 39 —
CAPLYTA
  • ITI, Inc. $47
$47 — —
ARISTADA
  • Alkermes, Inc. $20
$20 12 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record